Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cannabidiol in Children With Refractory Epileptic Encephalopathy: A Phase 1 Open Label Dose Escalation Study (CARE-E)

NCT03024827 is registered in ClinicalTrials.gov with University of Saskatchewan as lead sponsor.

NCT NCT03024827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03024827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cannabidiol in Children With Refractory Epileptic Encephalopathy: A Phase 1 Open Label Dose Escalation Study (CARE-E)
Lead sponsor
University of Saskatchewan
Phase
Phase 1
Overall status
Unknown status
Start date
April 26, 2017
Completion date
December 31, 2023
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

epileptic encephalopathy